Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03887143
Other study ID # NI18025HLJ
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 4, 2019
Est. completion date May 29, 2021

Study information

Verified date November 2021
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients


Description:

Arterial ischemic stroke outcomes benefited from the implementation of recanalization treatments (IV thrombolysis, endovascular treatments) and adapted management pathways in adult patients. Nevertheless randomized trials did not enroll patients under the age of 18 years old and data concerning these treatments in children are scarce. As it is much less frequent than in adults, recognition of stroke is often delayed in children. Consequently, acute phase trials are difficult to set up and perform. The phase I multicentric international prospective trial TIPS (Thrombolysis in Pediatric Stroke) was prematurely stopped because of poor enrollment. Published retrospective regional (Paris-Ile-de-France region, France) and national (Switzerland) studies addressed the feasibility of such treatments but, because of small samples (less than 20 patients in each study), efficiency and prognostic factors could not be addressed. Exhaustive retrospective studies in a definite geographic area but with a sufficient number of patients in a limited inclusion period would provide these crucial data and address these questions with good relevance and limited bias.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date May 29, 2021
Est. primary completion date May 29, 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Patients under 18 years old - Suspected or confirmed cerebral infarction - With recanalization treatment in the acute phase : intravenous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy - Patients treated between the January 2015, 1st and the May 2018, 31st - Collection of non-opposition from legal representatives Exclusion Criteria: - Refusal of the patient's legal representative to participate in the study

Study Design


Locations

Country Name City State
France Necker- Enfants Malades Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute management of stroke: Median time from symptom onset to Imaging (minutes) 1 day
Primary Acute management of stroke: Median time from symptom onset to beginning of recanalization treatment (minutes) 1 day
Primary Acute management of stroke: Median door-to-needle delay (minutes) 1 day
Secondary Treatment-emergent adverse events: Intracranial hemorrhage (yes/no) 7 days
Secondary Treatment-emergent adverse events: clinically symptomatic (yes/no) 7 days
Secondary Treatment-emergent adverse events: Peripheral hemorrhage (yes/no) 7 days
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis age of onset (year, months) 12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis Mechanism of stroke (CASCADE classification) 12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis stroke location (name of artery territory) 12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis time from symptom onset to beginning of recanalization treatment (minutes) 12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis initial imagine ASPECT Alberta Stroke Program Early CT Score. score (units on an scale). The ASPECTS score is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke. I has also been adapted to be used with MR scans.
All scale ranges : Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved (caudate, putamen, internal capsule, nsular cortex, M1(anterior MCA cortex=frontal operculum), M2(MCA cortex lateral to insular ribbon=anterior temporal lobe), M3(posterior MCA cortex=posterior temporal lobe, M4(anterior MCA territory immediately superior to M1), M5(lateral MCA territory immediately superior to M2), M6(posterior MCA territory immediately superior to M3)
For each scale, values better or worse :
In adults, an ASPECTS score less than or equal to 7 predicts a worse functional outcome at 3 months as well as symptomatic hemorrhage
12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis Association with :Modified Rankin Scale - mRS (Units on a scale)The mRS is a 6-point quantitative measure of functional independence.
All scale ranges:
0=No symptoms at all
No significant disability despite symptoms; able to carry out all usual duties and activities
Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance disability; requiring some help, but able to walk without assistance
Moderate
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
Severe disability; bedridden, incontinent and requiring constant nursing care and attention
Dead
For each scales range, values better or worse :
In the literature, good outcome is usually considered for patients with mRS [0-2]. Very good outcome is considered for patients with mRS [0-1]. We will use the same thresholds
12 months
Secondary factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis Association with :
- The Pediatric Stroke Outcome Measure - PSOM (Units on a scale) =scale has been designed and published to quantify functional consequences of stroke in children. The PSOM is a detailed neurological examination, with outcome scored in terms of degree of impairment in each of language, cognition, and sensorimotor. We wil use the PSOM-SNE version (PSOM-Short Neuro Exam version).
All scale ranges (0-0,5-1 or 2):
- Sensorimotor deficit, Language Deficit - Production, Language Deficit - Comprehension, Cognitive or Behavioural Deficit. Total score on 10
For each scale range, values better or worse:
Total impairment scores (out of a maximum of 10) will be considered as previously published, i.e. total score 0 or 0.5 representing good outcome, and poor outcome =1.
All subscales ranges (Normal, Anormal, Not Done):
Level of consciousness, Behaviour, mental status, Language, Cranial nerves, Motor testing, Tendon reflexes, Fine motor coordination, Sensory, Gate
12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03249844 - Paediatric Arteriopathy Steroid Aspirin Project Phase 3
Enrolling by invitation NCT06040255 - Focal Cerebral Arteriopathy Steroid Trial Phase 4
Completed NCT04962503 - A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Phase 2